喘中的新型潜在可治疗特征:研究将我们带到哪里?
Tara F Carr1, Michael C Peters2
1Asthma and Airway Disease Research Center, University of Arizona, Tucson, Ariz.
The journal of allergy and clinical immunology. Global
|October 2, 2023
概括
了解非2型喘机制是有限的. 本综述探讨了新出现的可治疗特征和新的子组,以推进喘治疗和药物开发.
科学领域:
- 肺病学和免疫学 肺病学和免疫学
- 翻译医学是一种翻译医学.
背景情况:
- 喘是一种复杂的疾病,基础机制尚不清楚.
- 目前将喘分为2型和非2型表型的分类可能过于简单.
- 对非2型喘的有限理解阻碍了治疗的发展.
研究的目的:
- 审查喘中新出现的可治疗的特征.
- 描述新的患者亚组和内型.
- 为了确定喘的新治疗点.
主要方法:
- 文献综述专注于喘表型,内型和可治疗的特征.
- 对非2型喘机制的新兴研究进行分析.
- 识别患者的特征,适应有针对性的治疗.
主要成果:
- 目前的2型/非2型喘分类需要改进.
- 正在确定非2型喘中的新型内型和患者子组.
- 新兴可治疗的特征为个性化喘治疗提供了潜力.
结论:
- 对喘异质性的更深入的理解至关重要.
- 识别可治疗的特征可以指导针对性喘治疗的开发.
- 对非2型喘机制的进一步研究对于推进治疗至关重要.
相关概念视频
Asthma: Pathogenesis and Management
433
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
433
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338


